Head and neck cancers are the sixth most common malignancy worldwide, accounting for approximately 6% of all cancer diagnoses and 1% to 2% of all cancer deaths.1 The complex anatomy and vital physiological role of the tumor-involved structures dictate that the goals of treatment are not only to improve survival outcomes but also to preserve organ function. The EXTREME regimen remains the evidence-based standard of care for first-line therapy for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).2 However, the emerging profile of immune checkpoint inhibitors (ICIs) presents clinicians and patients with alternative treatment options for R/M platinum-refractory cases, locally advanced (previously untreated) disease, and in a number of combinations (with other ICIs, as well as radio- and/or chemotherapy). The number of patients eligible for ICIs will increase as results from ongoing trials are reported, effectively creating a new continuum of care. Clinicians now face the challenge of determining how to sequence available therapies to prolong patient survival for as long as possible, while maintaining the highest possible quality of life.3 This interactive, interdisciplinary, case-based symposium will examine recommendations for team-based care as outlined in the current NCCN guidelines and explore optimal sequencing of treatment modalities for head and neck cancer, incorporating recent clinical trial data.

1Ferlay J, et al. Int J Cancer. 2010. 2Vermorken JB, et al. N Engl J Med. 2008. 3Argiris A, et al. Front Oncol. 2017.

View All Speakers


Maura Gillison, MD, PhD

Professor Department of Thoracic/Head and Neck Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX
View Full Bio

David Raben, MD

Professor Marsico Family Endowed Chair for Head and Neck Cancer Research Department of Radiation Oncology Anschutz Medical Campus University of Colorado Aurora, CO
View Full Bio

Ezra Cohen, MD

Professor of Medicine, Division of Hematology/Oncology University of California, San Diego (UCSD) Co-Director, San Diego Center for Precision Immunotherapy Associate Director for Translational Science Co-Leader, Solid Tumor Therapeutics Program Co-Director, Head and Neck Cancer Center of Excellence UCSD Moores Cancer Center La Jolla, CA
View Full Bio


In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of a CE Request Form, statements of credit for physicians will be issued within 30 business days.


Supported through an independent educational grant from AstraZeneca.